{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-094344","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.647183+00:00","generated_at":"2026-05-30T05:18:46.429633+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adial Pharmaceuticals appoints Vinay Shah as CFO effective Nov 16, 2024; Joseph Truluck resigns","bullets":["CFO Joseph Truluck resigns effective Nov 15, 2024; will serve as consultant through Mar 31, 2025.","Vinay Shah appointed CFO effective Nov 16, 2024, with a 3-year employment term.","Shah receives $315K annual base salary, up to 30% discretionary bonus, and 40,000 stock options.","Shah previously served as CFO at Virpax (VRPX) and Aravive (ARAV), with over 25 years industry experience.","Truluck's resignation was not due to any disagreement with the company over operations or accounting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-094344","json":"https://secwatch.observer/filing/0001213900-24-094344.json","markdown":"https://secwatch.observer/filing/0001213900-24-094344.md","text":"https://secwatch.observer/filing/0001213900-24-094344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/0001213900-24-094344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/ea0219983-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:18:46.429633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2db4be1216","claim":"Joseph Truluck resigned as Chief Financial Officer at ADIAL PHARMACEUTICALS, INC..","evidence_excerpt":"he would serve until November 15, 2024 as the Company’s Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/0001213900-24-094344-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c4dac40c74","claim":"Vinay Shah was appointed as Chief Financial Officer at ADIAL PHARMACEUTICALS, INC..","evidence_excerpt":"On November 1, 2024, the Company’s board of directors effective November 16, 2024 appointed Vinay Shah, age 61, as the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390024094344/0001213900-24-094344-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}